News

ASCO issues clinical practice guidelines for invasive cervical cancer


 

References

The American Society of Clinical Oncology (ASCO) has issued its first clinical practice guidelines on treating invasive cervical cancer, the first of its kind linking recommendations to resource availability.

“Access to cervical cancer care varies between regions of the world, both among and within countries. Lower resource settings tend to have limited or no cervical cancer screening programs. As a result, women often have advanced cervical cancer at diagnosis, which requires treatments that may not be readily available in these areas,” ASCO said in a written statement.

The recommendations, developed by a multidisciplinary panel from the United States, Spain, Mexico, Turkey, Canada, Argentina, Zambia, Uganda, South Korea, China, and India, provide guidance for four resource tiers: basic, limited, enhanced, and maximal. Optimal therapy and palliative care are recommended for each setting and for each stage of cervical cancer.

Concurrent radiotherapy and chemotherapy should be standard in enhanced and maximal settings for women with stage IB to IVA disease. In basic settings where patients cannot be treated with radiation therapy, extrafascial hysterectomy either alone or after neoadjuvant chemotherapy may be an option, the guidelines state. Other key recommendations can be found in the ASCO statement.

jcraig@frontlinemedcom.com

On Twitter @JessCraig_OP

Recommended Reading

New vulvar cancer guidelines stress regional disease control
MDedge ObGyn
Understanding ovarian germ cell neoplasms
MDedge ObGyn
Bone marrow transplant cures severe HPV disease in GATA2 immunodeficiency
MDedge ObGyn
Premenopausal age linked to lower sexual function after gynecologic cancer surgery
MDedge ObGyn
Primary care residents’ approach to HPV vaccine vary by specialty
MDedge ObGyn
Primary small cell cancer of the anus rare, but devastating
MDedge ObGyn
VIDEO: Should the HPV test be a stand-alone cancer screening test?
MDedge ObGyn
VIDEO: Is hysterectomy still best for complex atypical hyperplasia?
MDedge ObGyn
Patients: Intraperitoneal chemotherapy ‘worth it’ for ovarian cancer
MDedge ObGyn
Novel combination delays progression of recurrent gynecologic tumors
MDedge ObGyn